What should be the target blood pressure in heart failure patients with an implantable cardioverter defibrillator who already had ventricular tachycardia (VT), so as to prevent future VT and death?

Not Applicable

• Conditions: Heart failure; ventricular tachycardia; Hypertension; Implantable cardioverter defibrillator shocks; Cardiovascular - Other cardiovascular diseases; Cardiovascular - Hypertension

• Registration Number: ACTRN12620000764932
• Lead Sponsor: Sachin Nayyar

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-07-27
• Last Update Posted: 29 January 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1. Age 18-year to 80-years.
2. Heart failure due to ischemic or non-ischemic etiology of more than 3 months duration.
3. Left ventricular ejection fraction <40%.
4. History of spontaneous sustained VT.
5. Have an implantable cardioverter defibrillator (ICD) or consent to have one.
6. NYHA Class 1 -3.

Exclusion Criteria

1.VT related hospitalization within the last 3 weeks.
2.VT ablation in last 3 months.
3.Heart failure NYHA Class 4 or heart failure hospitalization within the last 3 weeks.
4.Resting systolic BP < 90mmHg at lowest doses of heart failure medication.
5.History of symptomatic systolic BP drop on standing.
6.Exercise induced systolic BP > 180mmHg or <90mmHg.
7.Known secondary cause of hypertension.
8.eGFR less than 30ml/min.
9.Intolerance to beta-blocker (equivalent to Metoprolol 12.5mg BD) (due to worsening of hypotension or heart failure).
10.Left ventricular ejection fraction <10%.
11.Suspected tachy-cardiomyopathy (arrhythmia as cause of heart failure).
12.Acute coronary event or stroke within the last 3 months.
13.Coronary revascularization within the last 3 months.
14.Expected survival less than 3 years due to terminal non-cardiac illness.
15.Severe pulmonary artery hypertension.
16.Large pericardial effusion.
17.Severe peripheral vascular disease or aortic aneurysm.
18.Non-compliance to medication.
19.Active alcohol or substance abuse.
20.Pregnancy.
21.Morbid obesity (BMI >40).
22.Remote residence out of reach to clinic sites.
23.Dementia or other cognitive impairment in ability to follow the protocol.
24.Current participation in another trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified